venerdì, 19 aprile 2024
30 Marzo 2018

ASCO and ESMO Value Frameworks May Be Beneficial in Determining Best Maintenance Therapies for Ovarian Cancer

March 26, 2018 – In recent years, the Food and Drug Administration approved several maintenance therapies for the management of platinum-sensitive recurrent ovarian cancer. Clinical trials that led to these approvals involved bevacizumab, TKIs, or PARP inhibitors. To access the value of the maintenance therapies and biomarkers to direct treatment, investigators from Duke University Medical Center; David Geffen School of Medicine at UCLA … (leggi tutto)